title: Olanzapine/fluoxetine combination vs. lamotrigine in the 6-month treatment of bipolar I depression.
abstract: To determine the efficacy and tolerability of olanzapine/fluoxetine combination (OFC) compared with lamotrigine (Lam) for long-term treatment of bipolar I depression, this 25-wk, randomized, double-blind study compared OFC (6/25, 6/50, 12/25, or 12/50 mg/d, n=205) with Lam titrated to 200 mg/d (n=205) in patients with bipolar I disorder, depressed. A protocol-specified analysis of 7-wk outcomes was previously reported. Outcome measures included Clinical Global Impressions-Severity of Illness (CGI-S) (primary), Montgomery-Asberg Depression Rating Scale (MADRS), and Young Mania Rating Scale (YMRS) scores. OFC-treated patients had significantly greater improvement than Lam-treated patients over 25 wk on CGI-S (p=0.008), MADRS (p=0.005), and YMRS (p<0.001) scores, and from baseline across visits from week 5 (titration complete) to the end of the study on CGI-S (p=0.043), MADRS (p=0.017), and YMRS (p=0.001) scores. Of patients in remission after the 7-wk acute phase, there was no significant difference between treatment groups in the incidence of relapse (MADRS >15, p=0.528). Rate of treatment-emergent mania was not significantly different by treatment (p=0.401). OFC-treated patients had more frequent (p<0.05) somnolence, increased appetite, dry mouth, sedation, weight gain, and tremor; Lam-treated patients had more frequent insomnia. There was a significant difference in incidence of treatment-emergent cholesterol > or = 240 (p<0.001) and in weight gain of > or = 7% (p<0.001) in favour of the Lam group. Patients with bipolar I depression had significantly greater symptom improvement over 25 wk on OFC compared with Lam. There was no treatment difference in incidence of relapse. OFC-treated patients had more treatment-emergent adverse events and greater incidence of weight gain and hypercholesterolaemia.
authors.affiliation: Lilly Research Laboratories, Indianapolis, IN 46285, USA. ebrown@lilly.com
authors.forename: Eileen
authors.initials: E
authors.lastname: Brown
authors.forename: David L
authors.initials: DL
authors.lastname: Dunner
authors.forename: Susan L
authors.initials: SL
authors.lastname: McElroy
authors.forename: Paul E
authors.initials: PE
authors.lastname: Keck
authors.forename: David H
authors.initials: DH
authors.lastname: Adams
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Degenhardt
authors.forename: Mauricio
authors.initials: M
authors.lastname: Tohen
authors.forename: John P
authors.initials: JP
authors.lastname: Houston
mesh_terms: D000293:Adolescent; D000328:Adult; D001569:Benzodiazepines / Q000627:therapeutic use*; D001714:Bipolar Disorder / Q000188:drug therapy* / Q000378:metabolism; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D005473:Fluoxetine / Q000627:therapeutic use*; D006801:Humans; D000077213:Lamotrigine; D008297:Male; D008875:Middle Aged; D000077152:Olanzapine; D011569:Psychiatric Status Rating Scales; D017367:Selective Serotonin Reuptake Inhibitors / Q000627:therapeutic use*; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome; D014227:Triazines / Q000627:therapeutic use*; D055815:Young Adult
chemical_list: D001569:Benzodiazepines; D002121:Calcium Channel Blockers; D005473:Fluoxetine; D000077213:Lamotrigine; D000077152:Olanzapine; D017367:Selective Serotonin Reuptake Inhibitors; D014227:Triazines